Cited 0 times in
Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유선 | - |
dc.contributor.author | 김현숙 | - |
dc.contributor.author | 박용정 | - |
dc.date.accessioned | 2014-12-19T17:43:17Z | - |
dc.date.available | 2014-12-19T17:43:17Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0001-2815 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/91929 | - |
dc.description.abstract | We investigated soluble human leukocyte antigen-G (sHLA-G) expression according to the phases of hepatitis B virus (HBV) infections and hepatocellular carcinoma (HCC). A total of 267 sera from anti-HBs positive healthy individuals (n = 50), chronic HBV carriers (n = 45), as well as patients with active hepatitis B (n = 46), liver cirrhosis (LC, n = 46) and early stage HCC (n = 80) were collected and assayed for sHLA-G. Relationships between sHLA-G levels and clinicopathologic parameters including HCC stages, differentiation grades, and levels of aminotransferases, HBV DNA and alpha-fetoprotein (AFP) were assessed. Concentrations of sHLA-G were higher in the active hepatitis B and HCC groups (median sHLA-G 53.7 and 178.8 U/ml, respectively) in comparison to other groups (P < 0.05), and there were no significant differences among sHLA-G levels of the anti-HBs positive, chronic HBV carrier and LC groups. Serum sHLA-G concentrations were not shown to be associated with clinicopathologic indices including the levels of aminotransferases, AFP, anti-HBs titer, HBV DNA, as well as HCC stages, numbers of tumor nodules, pathologic grades and presence of vessel invasion. The receiver-operating characteristic area under the curve (AUC) value of sHLA-G for differentiating HCC from LC was 0.98, which was greater than that of AFP (0.78) (P < 0.0001), and sensitivity and specificity of sHLA-G were, respectively, 90.0% and 95.7% for HCC when applying a cutoff level of 97.3 U/ml. Serum sHLA-G levels could be used as a diagnostic marker for HCC. Although sHLA-G levels did not reflect the severity of HBV infections and HCC, they were related with phases of the disease. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | TISSUE ANTIGENS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antibodies, Viral/blood | - |
dc.subject.MESH | Antibodies, Viral/immunology | - |
dc.subject.MESH | Area Under Curve | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Carcinoma, Hepatocellular/blood* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/immunology | - |
dc.subject.MESH | Carcinoma, Hepatocellular/virology | - |
dc.subject.MESH | Carrier State | - |
dc.subject.MESH | Case-Control Studies | - |
dc.subject.MESH | DNA, Viral/analysis | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | HLA-G Antigens/blood* | - |
dc.subject.MESH | HLA-G Antigens/immunology | - |
dc.subject.MESH | Hepatitis B virus/immunology* | - |
dc.subject.MESH | Hepatitis B, Chronic/blood* | - |
dc.subject.MESH | Hepatitis B, Chronic/immunology | - |
dc.subject.MESH | Hepatitis B, Chronic/virology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Cirrhosis/blood* | - |
dc.subject.MESH | Liver Cirrhosis/immunology | - |
dc.subject.MESH | Liver Cirrhosis/virology | - |
dc.subject.MESH | Liver Neoplasms/blood* | - |
dc.subject.MESH | Liver Neoplasms/immunology | - |
dc.subject.MESH | Liver Neoplasms/virology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Grading | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Sensitivity and Specificity | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | Solubility | - |
dc.subject.MESH | Transaminases/blood | - |
dc.subject.MESH | alpha-Fetoproteins/analysis | - |
dc.title | Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Y. Park | - |
dc.contributor.googleauthor | Y. Park | - |
dc.contributor.googleauthor | H. S. Lim | - |
dc.contributor.googleauthor | Y. S. Kim | - |
dc.contributor.googleauthor | D. J. Hong | - |
dc.contributor.googleauthor | H. S. Kim | - |
dc.identifier.doi | 22136460 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00785 | - |
dc.contributor.localId | A01582 | - |
dc.contributor.localId | A01117 | - |
dc.relation.journalcode | J02731 | - |
dc.identifier.eissn | 1399-0039 | - |
dc.identifier.pmid | 22136460 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1399-0039.2011.01814.x/abstract | - |
dc.subject.keyword | cancer diagnosis | - |
dc.subject.keyword | hepatitis B virus | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | human leukocyteantigen-G | - |
dc.contributor.alternativeName | Kim, Yu Seun | - |
dc.contributor.alternativeName | Kim, Hyon Suk | - |
dc.contributor.alternativeName | Park, Yong Jung | - |
dc.contributor.affiliatedAuthor | Kim, Yu Seun | - |
dc.contributor.affiliatedAuthor | Park, Yong Jung | - |
dc.contributor.affiliatedAuthor | Kim, Hyon Suk | - |
dc.citation.volume | 79 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 97 | - |
dc.citation.endPage | 103 | - |
dc.identifier.bibliographicCitation | TISSUE ANTIGENS , Vol.79(2) : 97-103, 2012 | - |
dc.identifier.rimsid | 30011 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.